How to Localize Labels and Instructions for Overseas Registration of Home Medical Devices

Published: July 30, 2026 17:38

Updated: July 30, 2026 17:38

Executive Summary

Localizing labels and instructions is a critical threshold for home medical device overseas registration. Localization is not only language translation but also involves adapting to target country regulatory requirements, determining product classification and corresponding registration pathway, aligning technical documentation, and allocating post-market maintenance responsibilities. Enterprises should first determine the regulatory status of the product in the target country, identify the risk class and registration category, and then evaluate the degree to which existing NMPA, CE, or FDA certification documentation can be reused, with special attention to symbols, warning statements, units of measurement, language requirements, and format specifications.

Common risks include failure to use official language, omission of mandatory information, non-compliant symbols, inconsistency with registration documentation, and failure to appoint a local agent or authorized representative. When preparing materials, enterprises must provide label specimens in the target country format, electronic copies of instructions, packaging design drawings, and supporting documents such as declarations of conformity, risk management reports, and clinical evaluation summaries. For multi-country registration, adopting a strategy of a unified core file plus localized difference packages can effectively reduce the burden of duplicate preparation and amendment requests.

Enterprises must understand that once localized labels and instructions are submitted, they become part of the registration dossier. Subsequent changes require compliance with reporting procedures. Therefore, upfront investment in thorough verification is essential.

Applicable Scenarios and Core Issues

Overseas registration of home medical devices involves multiple countries or regions, and regulatory requirements for labels and instructions vary significantly across markets. Common scenarios include applying for the first registration in GHWP member countries (e.g., ASEAN, Saudi Arabia, Brazil) for a product already marketed in China, or expanding into multiple countries based on existing CE or FDA certification. The core issue is how to ensure that every element of the label and instructions meets the mandatory requirements of the target country while avoiding contradictions with the registration technical documentation. For example, the symbols required under the EU MDR (ISO 7010) may differ from those mandated by Brazil's Anvisa. Saudi Arabia requires bilingual Arabic and English labels and mandates that local authorized representative information be listed. Ignoring such details can directly lead to amendment requests or registration failure.

Another critical dimension is product classification. Home blood pressure monitors, glucose meters, thermometers, oxygen concentrators, and ventilators may be classified as Class II, IIb, or even Class III in different countries. The level of detail required in labels and instructions is directly linked to classification. Higher-risk products typically require more detailed warnings, usage restrictions, and clinical data references. Enterprises should clarify the target market's regulatory system at the project outset: whether MDSAP member states' mutual recognition applies, whether existing CE technical documentation can be leveraged, and whether a local marketing authorization holder is required.

Registration Decision Logic

Localization work must be based on a clear registration decision logic.

• First, determine whether the product falls within the scope of medical device regulation in the target country. Some home health products (e.g., smart wristbands, health scales) may not be regulated as medical devices in certain countries, leading to different label requirements.
• Second, identify the risk class and registration pathway. For instance, a product classified as Class II in China under NMPA may require notified body review under the EU MDR as Class IIa or IIb when exported to Europe.
• Third, assess the reusability of existing documentation. Companies with ISO 13485 or MDSAP certificates can share quality system documentation, but labels and instructions must be localized for each market.
• Fourth, confirm that the clinical evaluation portion of the technical documentation supports the claims on the local label. For example, blood glucose meters must reference clinical accuracy data, and oxygen concentrators must specify the oxygen flow range.

The application entity also influences the localization strategy. If a local authorized representative or local agent is appointed as the registrant, its name and address must appear on the label, and that party bears legal responsibility for label content. Enterprises should establish agreements in advance to clearly define change notification obligations. For multi-country registration, it is recommended to use an English master file as the basis and create a difference package for each market. For example, common safety descriptions, intended purpose, and warnings can reside in the master file, while country-specific regulatory information, languages, and symbol lists are placed in the difference package.

Documentation and Evidence

When preparing localized labels and instructions, enterprises must collect and provide the following materials to demonstrate compliance:

• Final versions of labels and instructions in the target country's official language(s) (e.g., French, German, Portuguese, Arabic).
• A symbol list and source description (whether symbols are derived from ISO 7010, IEC 60417, or other officially recognized standards).
• Consistency comparison tables between text content and registration technical documentation (e.g., contraindications and warnings in the instructions must match the risk management report).
• Packaging layout drawings, including label layout, dimensions, and printing color requirements.
• Translation accuracy statements, preferably issued by a certified translation agency.
• Supplementary instructions for special populations (e.g., children, pregnant women, elderly).

In addition, physical photographs of the device should be provided to verify label placement, adhesion, and durability. For home devices with embedded software, the interface text also falls within the scope of labels and instructions and must be localized.

When reusing existing CE or FDA technical documentation, the clinical evaluation report and risk management report must be updated to ensure that localized label content does not alter the safety and performance claims. If localization changes the wording of warnings or intended purpose, it may trigger reassessment of equivalence or even new clinical investigations. Therefore, it is strongly recommended to maintain strict technical language consistency during localization and only adjust regulatory information (e.g., registrant name, address) and language translation.

Common Errors

• Directly translating Chinese labels into the target language without considering local standard symbol requirements, resulting in invalid graphical symbols.
• Omitting mandatory information in the instructions, such as Anvisa registration numbers in Brazil or the CE mark and notified body number in the EU.
• Failing to convert measurement units (e.g., inches/centimeters, pounds/kilograms, Fahrenheit/Celsius), leading to user confusion.
• Not specifying or incorrectly listing local authorized representative information, causing the product to be deemed illegally marketed.
• Contradictory content between labels and instructions, such as described battery type not matching the actual label.
• Using prohibited claims, such as “treatment” instead of “management” or “monitoring,” exaggerating the intended purpose.
• Ignoring version control and failing to synchronize multiple language versions after updates, leading to version confusion.
• Not allocating sufficient time for official translation approval, delaying the registration timeline.

Enterprise Preparation Checklist

• Confirm the target country regulatory body's language requirements for labels and instructions (whether English is accepted or local language is mandatory).
• Collect applicable label and instruction standards in the target country (e.g., ISO 15223-1, IEC 60601-1-11, and member state supplemental guidelines).
• Establish a core label database (English master file) containing all universal safety information, warnings, intended purpose, and contraindications.
• Create a localized difference package for each target market, including official language versions, local authorized representative information, and special symbols.
• Complete translation and conduct internal review or third-party review to ensure terminology accuracy and consistency with registration documents.
• Design label layouts and produce physical samples to test label durability under anticipated conditions (e.g., alcohol wiping, humidity).
• Obtain translation accuracy declarations and symbol conformity declarations.
• Maintain version control records to ensure synchronized updates across multiple language versions.
• Communicate with the local authorized representative/agent to confirm their name, address, and contact details.
• Prepare electronic and paper instruction samples for registration submission, as well as physical label photographs.

AIMEILI Perspectives

The most common misconception is that translation alone completes localization. In reality, localization is essentially a regulatory compliance transformation. We recommend mapping out the regulatory differences across target markets early in the project, rather than jumping straight into translation.

Regarding document reuse, quality management system files, risk management files, and core scientific content from clinical evaluation reports can be reused, but regulatory information, symbols, measurement units, and languages on labels and instructions must be recreated. Multi-country registration should never be prepared in isolation for each country. Instead, establish a unified master file plus difference package structure, which significantly reduces duplicate preparation and amendment risk.

Another critical reminder: control over the local agent or authorized representative is paramount. If the agent holds the registration certificate, the enterprise may become passive during future changes or renewal. Therefore, contracts should clearly define the agent's scope of responsibility, certificate ownership, and obligation to cooperate during changes.

For post-market maintenance, once labels or instructions are updated, enterprises must assess whether the change affects the registration and notify the regulatory authority in a timely manner. We often see companies update instructions on their official website without notifying the notified body, resulting in a finding of non-compliance with technical documentation consistency. In summary, localization is not a simple outsourced translation task. It is a strategic activity requiring collaboration among regulatory, quality, engineering, and marketing departments.

Frequently Asked Questions

Q: What are the core differences in label localization between exporting to the EU and Southeast Asia?

Under the EU MDR, labels must include the CE mark and notified body number, and official language requirements vary by country; English may be partially accepted, but the instructions often require the destination country's language. Southeast Asian countries differ significantly: Thailand requires Thai labels, Malaysia accepts English, Indonesia requires Indonesian, and most countries require local agent information. The EU also emphasizes the conditions for using electronic instructions (eIFU), while Southeast Asia relies more on paper instructions. Additionally, the EU strictly follows symbol standards from EN 980 (now withdrawn) and ISO 15223-1, whereas Southeast Asian countries may adopt international standards or have their own derived requirements.

Q: Can labels and instructions from an existing domestic Class II product be directly reprinted for export?

Absolutely not. The warning statements, contraindications, and registration numbers required by China's NMPA are completely different from overseas markets. For example, blood pressure monitors sold in China must state “Only for measuring blood pressure, not suitable for neonates,” while exports to the US FDA require revalidation under AAMI/ISO 81060 standards and revised claims. Furthermore, measurement units differ; blood pressure is commonly expressed in mmHg globally, but temperature units in the US and Europe often use Fahrenheit. Content must be redesigned according to the target country's regulations and standards.

Q: Do localized labels and instructions require notarization or certification?

Some countries require notarization of translated texts or certification by certified translators. For example, Brazil's ANVISA requires Portuguese instructions to be submitted by a Brazilian registered translation agency; Saudi Arabia requires documents to be notarized by the Saudi embassy in China. Enterprises should consult local agents or official guidelines in advance to avoid discovering missing certifications during review. For high-risk products, some regulators may also require official translation certification of clinical evaluation report content.

Implementation Recommendations

In practice, enterprises should break the issue down into five tasks: regulatory judgment, document preparation, evidence reuse, localization conversion, and post-market maintenance, rather than having one department temporarily compile documents. This approach allows for earlier identification of document gaps and ensures that sales, R&D, quality, and regulatory teams have a consistent understanding of target country requirements.

If the company plans to enter multiple markets simultaneously, it is recommended to first form a unified core technical file, then supplement authorizations, labels, languages, forms, and local agent documentation for each country. The efficiency of multi-country registration often depends on whether the initial document framework is unified, rather than the submission speed of a single country.

• First, confirm whether the product is within the scope of medical device regulation in the target country.
• Then confirm the risk class, registration pathway, and application entity.
• Verify that technical documentation, quality system, and clinical evidence support each other.
• Clarify local agent, authorized representative, and certificate control rights.
• Establish post-market change, renewal, and vigilance event maintenance mechanisms.

Related Reading

• How to Organize Technical Documentation for Overseas Registration of Home Medical Devices
• How to Prepare Clinical Evaluation Materials for Overseas Registration of Home Medical Devices
• Why Do POCT Product Overseas Registration Timelines Get Extended?
• What Are Common Reasons for POCT Product Overseas Registration Amendment Requests?
• How to Perform Post-Market Surveillance for POCT Products?
• When Should POCT Product Registration Changes Be Submitted?
• What Preparations Are Needed Before POCT Product Renewal?
• How to Group Multiple Models for POCT Product Registration?

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principles: priority is given to official regulatory agencies, international organizations, standard bodies, and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicability boundary: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of target country regulatory authorities, testing conclusions, or legal advice.